One Health and vector-borne diseases module
WHO congratulates Benin and Mali for eliminating trachoma as a public health problem
WHO advises not to use non-sugar sweeteners for weight control in newly released guideline
Fifth Meeting of the International Health Regulations (2005) (IHR) Emergency Committee on the Multi-Country Outbreak of monkeypox (mpox)
The WHO Director-General transmits the report of the fifth meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the multi-country outbreak of monkeypox (mpox), held on Wednesday 10 May from 12:00 to 17:00 CET.
The Emergency Committee acknowledged the progress made in the global response to the multi-country outbreak of mpox and the further decline in the number of reported cases since the last meeting. The Committee noted a significant decline in the number of reported cases compared to the previous reporting period and no changes in the severity and clinical manifestation of the disease. The Committee acknowledged remaining uncertainties about the disease, regarding modes of transmission in some countries, poor quality of some reported data, and continued lack of effective countermeasures in the African countries, where mpox occurs regularly. The Committee considered, however, that these are long-term challenges that would be better addressed through sustained efforts in a transition towards a long-term strategy to manage the public health risks posed by mpox, rather than the emergency measures inherent to a public health emergency of international concern (PHEIC).
The Committee emphasised the necessity for long-term partnerships to mobilize the needed financial and technical support for sustaining surveillance, control measures and research for the long-term elimination of human-to-human transmission, as well as mitigation of zoonotic transmissions, where possible. Integration of mpox prevention, preparedness and response within national surveillance and control programmes, including for HIV and other sexually transmissible infections, was reiterated as an important element of this longer-term transition. In particular, the Committee noted that the gains in control of the multi-country outbreak of mpox have been achieved largely in the absence of outside funding support and that longer-term control and elimination are unlikely unless such support is provided. These sustained investments will, in the long run, save money and lives, and reduce the risk of a global resurgence of mpox, as well as the risk of reverse zoonosis resulting in new areas where the virus may circulate.
The WHO Director-General expresses his gratitude to the Chair, Members, and Advisors for their advice and concurs with this advice that the event no longer constitutes a PHEIC for the reasons detailed in the proceedings of the meeting below and issues revised Temporary Recommendations for the transition period, which are presented at the end of this document.
The fifth meeting of the IHR Emergency Committee on the multi-country outbreak of mpox was convened by videoconference, with the Chair and Vice-Chair being present in person at WHO headquarters, in Geneva, Switzerland. Eleven of the fifteen Members and five of the nine Advisors to the Committee participated in the meeting.
In his opening remarks, the WHO Director-General welcomed the Committee, and noted a sustained decline in cases globally, with almost 90% fewer cases reported in the last three months, compared with the previous three months. The Director-General also noted that, while there is a downward trend globally, the virus continues to transmit in certain communities. He further stressed the importance for countries to maintain their surveillance and response capacities, and to continue to integrate mpox prevention and care into existing national health programmes to address future outbreaks.
The Office of Legal Counsel’s representative briefed the Committee Members and Advisors on their roles, responsibilities, and mandate under the relevant articles of the IHR. The Ethics Officer from the Department of Compliance, Risk Management, and Ethics reminded Members and Advisors of their duty of confidentiality as to the meeting discussions and the work of the Committee, as well as their individual responsibility to disclose to WHO in a timely manner any interests of a personal, professional, financial, intellectual or commercial nature that may give rise to a perceived or direct conflict of interest.
The meeting was handed over to the Chair of the Emergency Committee, Dr Jean-Marie Okwo-Bele, who introduced the objectives of the meeting: to provide views to the WHO Director-General as to whether the multi-country outbreak of mpox continues to constitute a PHEIC, and, if so, to review the proposed Temporary Recommendations to States Parties.Presentations
Representatives of Japan, Nigeria and the United Kingdom of Great Britain and Northern Ireland provided updates on the current epidemiological situation in their countries and on the public health measures being implemented.
The Secretariat provided a comprehensive update on the epidemiological situation and the current response efforts, with the WHO Region of Africa providing an additional regional update. The WHO Region of Africa reported that more than 1500 cases were confirmed since January 2022 in 13 countries, with the majority of these cases being reported from Nigeria and the Democratic Republic of the Congo. There was little information on modes of transmission and the quality of reported data through the surveillance systems was uneven in the African Region.
The Secretariat informed that the current global risk of the mpox multi-country outbreak is assessed as remaining moderate globally and in four of the WHO regions and remaining low in South-East Asia and the Western Pacific Regions. Further details can be found in the 22nd External situation report. All data are available, and case counts are updated weekly at this link - 2022 Monkeypox Outbreak: Global Trends.
The Secretariat further informed the Committee that the WHO Monkeypox Strategic preparedness, readiness and response plan will come to an end in June 2023, and that there are plans to develop a long-term strategy for the control and eventual elimination of human-to-human transmission, and mitigating the zoonotic transmission where it occurs, along with a country planning guide to support the implementation of this strategy.
After the presentations, Committee Members and Advisors proceeded to engage the Secretariat and the presenting countries in a question-and-answer session.
The Committee reconvened in a closed meeting to examine the questions in relation to whether the event continues to constitute a PHEIC, and to advise on the proposed Temporary Recommendations, in accordance with IHR provisions.
The Committee acknowledged the continued progress since the last meeting in reducing the number of cases and deaths, and the lack of significant changes in the demographics and severity of clinical manifestations, with the major factors contributing to deaths and severity continuing to be related to untreated HIV infections and immunosuppression. The Committee, however, recognized some remaining concerns, including duration of immunity following infection or vaccination, with breakthrough infections in fully vaccinated persons and cases of reinfection; insufficient evidence about vaccine effectiveness; and the poor quality of data and inconsistency in reporting of cases to WHO, particularly in countries where the disease occurs regulalry.
The Committee also noted no changes in the risk assessment since the last meeting. Some uncertainties were raised regarding the potential impact of upcoming large social gatherings among high-risk groups, although it was noted that such gatherings held in some countries during the last year and recently did not lead to spikes in the number of cases. In addition, it was noted that some regions have started to develop post-emergency plans and have begun integration of the response into sexually transmissible infection programs.
The Committee expressed concerns about the persisting knowledge gaps related to mpox in Africa, the lack of access to vaccines, medicines, and diagnostic testing capacities in many low-income countries; the recurring zoonotic transmission in Africa; and the fact that not all countries are receiving the support they need or have structures or systems to respond to mpox, including inadequate support for marginalized groups.
In conclusion, having considered the significant decline in the global spread of mpox and the gains achieved in the control of the outbreak in many countries, the Committee advised that the event requires a transition from a PHEIC to a robust, proactive and sustainable mpox response and control program, that prevents resurgence of global spread, aims to eliminate person-to-person transmission, and mitigates the impact of local spill-over effects. The Committee emphasized the need for long-term attention and support, including financial support, particularly for countries where mpox occurs regularly, and advised that Standing Recommendations under the IHR would now be a more appropriate tool to manage the immediate, short and long-term public health risks posed by mpox.
The Committee emphasized the need to rally partners and resources for a sustained WHO-led strategy to improve surveillance, research and control measures, and to prioritize and invest in African countries and other underserved communities where mpox readiness and response efforts still remain inadequate. These investments should target surveillance, laboratory testing, data quality, access to vaccines and therapeutics, risk communication and community engagement, and research, among other identified gaps
The Committee provided advice on the draft Temporary recommendations, with the understanding that such Temporary recommendations may continue to be issued by the WHO Director-General if needed after the termination of the PHEIC. The Committee also emphasized the need for IHR States Parties to strengthen their commitments and accountability in the implementation of the temporary recommendations. Further, the Committee recommended vigilance about any new, significant event or the emergence of new knowledge that might require reconsidering mpox as a PHEIC.
These Temporary Recommendations continue to support the goal of the WHO Strategic Preparedness, Readiness and Response Plan for Monkeypox 2022–2023 and WHO operational guidelines to stop the outbreak and meet the objectives to interrupt human-to-human transmission, protect the vulnerable, and minimize zoonotic transmission of the virus.
Any State Parties may experience importation or local transmission of mpox and some States Parties may also be experiencing zoonotic transmission. These Temporary Recommendations apply to all States Parties in all stages of mpox readiness or response, as outlined in previous sets of Temporary Recommendations, in order to further support mpox control and eventual elimination of human-to-human transmission. States Parties in a position to support scaling up access to medical countermeasures in low- and middle-income countries should continue to do so.
In implementing these Temporary Recommendations, States Parties should ensure full respect for the dignity, human rights and fundamental freedoms of persons, in line with the principles set out in Article 3 of the IHR. The WHO advises States Parties to maintain readiness and response capacity in collaboration with key communities, partners and other stakeholders through a One Health approach.
To meet the objectives above, States Parties should:
- Sustain and promote key elements of the mpox response strategy and review their experience to inform public health policies, programmes and actions.
- Develop and implement integrated mpox control plans and an elimination strategy with the aim of preventing and stopping human-to-human transmission and/or mitigating zoonotic transmissions, as appropriate.
- Maintain epidemiological surveillance of mpox, making every effort to ensure laboratory confirmation of suspected cases and reporting to WHO of confirmed and probable cases, according to variables defined in the WHO Case Reporting Form.
- Report immediately all confirmed travel-related mpox cases to WHO through channels established under IHR provisions.
- Integrate mpox detection, prevention, care and research with existing and innovative HIV and sexually transmitted disease prevention and control programmes, and other health services as appropriate.
- Sustain and invest in risk communication and community support and engagement for affected communities and at-risk groups, including through health authorities and civil society.
- Continue to implement interventions to avoid stigma and discrimination against any individuals or group that may be affected by mpox.
- Support and enhance access to diagnostics, vaccines and therapeutics to advance global health equity, in particular for most affected communities worldwide, including gay, bisexual and other men who sex with men, with special attention to those most marginalized within those groups, and in resource-constrained countries where mpox is endemic.
- Continue to strengthen diagnostic capacity, decentralized access to testing, and genomic sequencing, including sharing of genetic sequence data through public databases.
- Continue to make vaccines available for primary preventive (pre-exposure) and post-exposure vaccination for persons and communities at high risk of mpox.
- Ensure provision of optimal clinical care with infection prevention and control measures in place for suspected or confirmed mpox in all clinical settings. Ensure training of health care providers accordingly.
- Strengthen capacity in resource-limited and rural settings where mpox continues to occur, to better understand modes of transmission, quantify resource needs, and respond to outbreaks and sustained chains of transmission.
- Implement a coordinated research agenda to generate and promptly disseminate evidence for key scientific, social, clinical and public health aspects of mpox prevention and control. Continue clinical trials of medical countermeasures, including vaccines, therapeutics, and diagnostics, in different populations, in addition to monitoring of vaccine safety, effectiveness and duration of protection from infection and vaccination.
- Countries in West, Central and East Africa where mpox is endemic should make additional efforts to elucidate mpox-related risk, vulnerability and impact and to investigate, understand and control mpox in their respective settings, including the consideration of zoonotic, sexual and other modes of transmission in different demographic groups.
Detailed Temporary Recommendations issued on 15 February 2023 following the 4th IHR Emergency Committee meeting remain technically valid for all States Parties. All current WHO interim technical guidance and WHO operational guidance can be found on the WHO website. To follow on from the existing Strategic Preparedness, Readiness and Response Plan, WHO will release an overarching global strategy and new country planning guide for mpox elimination and control.
Increase in cases of carbapenem-resistant E. coli carrying the blaNDM-5 gene, EU/EEA countries
Weekly COVID-19 country overview
WHO calls for accelerated action to reduce anaemia
152 million babies born preterm in the last decade
Celebrating Europe Day 2023
Lifesaving solution dramatically reduces severe bleeding after childbirth
Global progress in tackling maternal and newborn deaths stalls since 2015: UN
Improving sustainability through One Health approaches: an interview with Professor Rosenbaum Nielsen
UAE and WHO deliver air lift of critical medical supplies to Sudan
The United Arab Emirates (UAE) and the World Health Organization have delivered 30 tons of urgent medical supplies to Sudan today. A plane carrying supplies for injury treatment, emergency surgeries, and essential drugs arrived in Port Sudan Airport early this morning.
The shipment, valued at US$ 444 000, is the first that WHO has been able to deliver by air to Sudan since the outbreak of the conflict. WHO distributed supplies to heath facilities prior to the escalation of conflict. These were exhausted after a few days given the number of injured.
The dispatch of the aircraft comes as part of the UAE's continuous relief efforts in support of the Sudanese people and reflects its deep relations with Sudan, particularly in light of the current situation the country is facing. The relief is also an extension of the UAE’s humanitarian vision and underscores its relations with other countries based on human fraternity and its commitment to assisting others during crises and emergency situations.
Dr Reem bint Ebrahim Al Hashimy, Minister of State for International Cooperation, said that the UAE "continues to work closely alongside the World Health Organization to ensure the successful deployment of the critical logistics operations to send urgent medical and food aid to help address the current crisis in Sudan. In parallel with calls for all sides of the current conflict to immediately cease hostilities and de-escalate a situation that is causing untold suffering for the Sudanese people, the UAE is steadfast in its commitment to providing aid and assistance to countries in times of need. The UAE is particularly focused on providing for the most vulnerable groups affected by the situation in Sudan, especially the sick, children, the elderly, and women who are most at risk from the ongoing concerning conflict – and these relief flights will directly address the most pressing gaps in medical and food provision. The UAE's deeply held humanitarian values have meant that it has ensured it has continued to communicate to the world its robust and unrelenting dedication to strengthening peace, security and stability, not just regionally, but also worldwide, whilst alongside its partners and the international community, the country continues to assist the Sudanese people in times of crisis.”
The health supplies include enough trauma, emergency surgical supplies, and essential medicines to immediately reach 165 000 people who are in desperate need of humanitarian aid. Health facilities across the country report they have run out of basic health supplies and that national medical stores are no longer accessible due to the security situation. Among other support, WHO is deploying two emergency logisticians travelling with the cargo to ensure that these supplies are immediately distributed to 13 major health facilities to support healthcare workers and extend care to those in need.
WHO has another 30 metric tons of supplies for malaria and noncommunicable diseases like diabetes and hypertension, conditions that can become deadly if left untreated. These and about 23 000 blood bags are being readied within the WHO global logistics hub in the International Humanitarian City, and WHO is currently exploring all possibilities for delivering these supplies to Sudan as quickly as possible in collaboration with the Sudanese Ministry of Health.
Dr Michael Ryan, Executive Director, of the WHO Health Emergencies Programme, said, “The WHO Global Logistics Hub in the UAE has become a centerpiece of rapid supply response to acute events globally. Supporting over 140 countries across all 6 WHO geographic regions, the hub provides a lifeline to Member States experiencing health emergencies arising from outbreaks of diseases, disasters such as floods and earthquakes, and the impact of conflict on health systems. The support provided by the UAE enables WHO to be at the forefront of these health emergency responses – delivering specialist medical aid to those in need wherever and whenever it is needed. As part of efforts to strengthen the global architecture for health emergency preparedness, response, and resilience the UAE, WHO, and partners are working hand-in-hand to deliver supplies to reach the world’s most vulnerable in their time of greatest need.”
For his part, Dr Ahmed Al-Mandhari, WHO Regional Director for the Eastern Mediterranean, said, “The World Health Organization continues to coordinate with the Sudanese health authorities to deliver essential health supplies through all available pathways. Due to the conflict, hospitals, pharmacies and primary health care facilities have stocked out of essential, life-saving medicines. The arrival of an additional 30 metric tons of trauma and emergency surgery supplies as well as essential medicines will enable WHO to support 13 major health facilities and re-establish health care services for those in need. Our global logistics hub in Dubai plays a vital role in ensuring an uninterrupted supply of health commodities and we are grateful for the support provided by the United Arab Emirates to facilitate our first charter flight of these desperately needed supplies. It is support such as this that shows in action our Regional vision of health for all, by all.”
The medical aid provided by the World Health Organization through the UAE accounted for approximately 55% of the total medical supplies provided to Sudan from abroad in 2022, reflecting the UAE's position as a major hub for international humanitarian assistance.
Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic
World Hand Hygiene Day 2023
Nearly 20 000 surgical site infections reported during 2018-2020
ECDC: On Air - Episode 37 - All (Clean) Hands on Deck
Collaborating locally is key for progress globally towards health-related SDGs
A new progress report is being jointly released today by the 13 signatory agencies of the Global Action Plan for Healthy Lives and Well-being for All (SDG3 GAP). The report entitled “What worked? What didn’t? What’s next?” reflects four years of joint work by major multilateral agencies outlining what has and has not worked in strengthening collaboration and support to accelerate country progress towards health-related Sustainable Development Goals (SDGs).
This year marks the halfway point toward the SDGs, but the world is lagging behind to reach the global goals. Since its launch in 2019, the SDG3 GAP enabled creation of new collaboration structures between the signatory agencies in key areas such as sustainable financing and primary health care among others. At least 67 countries engaged in on one or more of the SDG3 GAP accelerator themes.
"We have made important progress, but we still have a long path to travel to improve the way that multilateral organizations work together to support countries. We must listen to what countries tell us and act upon their guidance,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General and Chair of the SDG3 GAP Principals Group. “I thank the partners for their collaboration and for the honest self-assessments contained in this report."
The report provides six key recommendations to ensure that countries benefit from a more streamlined support and to realize the commitments made in the SDG3 GAP. These include:
- continue the SDG3 GAP improvement cycle for health by seeking the views of Member States on how we collaborate at country-level and responding to related recommendations;
- maintain GAP as a platform for collaboration;
- foster stronger collaboration at the country level on primary health care and explore new thematic topics such as climate resilient health systems;
- jointly apply new approaches at country level such as the delivery for impact approach;
- engage more with civil society; and
- work with Member States to strengthen incentives for collaboration through political leadership, governance direction and funding to support collaboration.
Key findings of the report will feed into discussions of the next United Nations General Assembly SDG Summit and the High-level Meeting on Universal Health Coverage in September 2023.
The months leading up to these key events provide an opportunity for a joint push by Member States and multilateral agencies to identify ways on how to implement the recommendations and to prepare the ground to fully leverage stronger collaboration and accelerate progress towards the health-related SDGs in the second half of the SDG timeframe.
Note to the editor:
The SDG3 GAP describes how the 13 signatory agencies will adopt new ways of working, building on existing successful collaborations, and jointly align their support around national plans and strategies that are country-owned and -led. The signatories to the SDG3 GAP are Gavi, the Vaccine Alliance; Global Financing Facility for Women, Children and Adolescents (GFF); Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund); International Labour Organization (ILO); Joint United Nations Programme on HIV/AIDS (UNAIDS); United Nations Development Programme (UNDP); United Nations Population Fund (UNFPA); United Nations Children’s Fund (UNICEF); Unitaid; United Nations Entity for Gender Equality and the Empowerment of Women (UN Women); World Bank Group; World Food Programme (WFP); and World Health Organization (WHO). See full report, What Worked? What didn’t? What’s next?